Targeting Cancer with Amino-Acid Auxotroph Salmonella typhimurium A1-R

Chapter
First Online:

Abstract

Salmonella, Clostridium and Bifidobacterium have been shown to ­control tumour growth and promote survival in animal models. However, Clostridium and Bifidobacterium are obligate anaerobes which limits their growth to the necrotic region of tumour and thus limits their effectiveness. In contrast, Salmonella is a facultative anaerobe which can grow in the viable as well as necrotic regions of tumours giving it greater potential as an anti-tumour agent. However, previous experiments with Salmonella, including clinical trials, have used over-attenuated mutants, limiting the anti-tumour efficacy. We have developed an effective bacterial cancer therapy strategy using Salmonella typhimurium auxotrophs which grow in viable as well as necrotic areas of tumours. The auxotrophy severely restricts growth of these bacteria in normal tissue. The S. typhimurium A1-R mutant, which is auxotrophic for leu-arg, has high anti-tumour virulence. In vitro, A1-R infects tumour cells and causes nuclear destruction. A1-R was initially used to treat metastatic human prostate and breast tumours that had been orthotopically implanted in nude mice. Forty percent of treated mice were cured completely and survived as long as non-tumour-bearing mice. A1-R administered i.v. to nude mice with primary osteosarcoma and lung metastasis was highly effective, especially against metastasis. A1-R was also targeted to both axillary lymph and popliteal lymph node metastasis of human pancreatic cancer and fibrosarcoma, respectively, as well as lung metastasis of the fibrosarcoma in nude mice. The bacteria were delivered via a lymphatic channel to target the lymph node metastases and systemically via the tail vein to target the lung metastasis. The metastases were cured without the need of chemotherapy or any other treatment. A1-R was administered intratumorally to nude mice with an orthotopically transplanted human pancreatic tumour. The primary pancreatic cancer regressed without additional chemotherapy or any other treatment. A1-R was also effective against pancreatic cancer liver metastasis when administered intrasplenically to nude mice. A1-R was also highly effective against spinal cord glioma in orthotopic nude mouse models, a highly treatment-resistant disease. Tumour vascularity positively correlates with susceptibility to A1-R therapy. Substrains with tumour-specific promoters and mutants which enhance selective tumour targeting have been identified. The approach described here, where bacterial monotherapy effectively treats ­primary and metastatic tumours, is a significant improvement over previous bacterial tumour therapy strategies that require combination with toxic chemotherapy.

Keywords

S. typhimurium Leucine-arginine auxotrophs Cancer therapy Green fluorescent protein Red fluorescent protein Fluorescence Imaging Mice Nude mice Tumour targeting 

Abbreviations

5-FU

5-fluorouracil

FACS

Fluorescence-activated cell sorting

FNR

Fumarate and nitrate reduction global regulator

GFP

Green fluorescent protein

HIP-1

Hypoxia-inducible promoter

LLC-RFP

Lewis lung carcinoma expressing red fluorescence protein

ND-GFP

Nestin-driven GFP

NTG

Nitrosoguanidine

RFP

Red fluorescent protein

VEGF

Vascular endothelial growth factor

This is a preview of subscription content, log in to check access.

References

  1. Arrach N, Zhao M, Porwollik S et al (2008) Salmonella promoters preferentially activated inside tumors. Cancer Res 68:4827–4832PubMedCrossRefGoogle Scholar
  2. Arrach N, Cheng P, Zhao M et al (2010) High-throughput screening for Salmonella avirulent mutants that retain targeting of solid tumors. Cancer Res 70:2165–2170PubMedCrossRefGoogle Scholar
  3. Bermudes D, Low B, Pawelek J (2000) Tumor-targeted Salmonella. Highly selective delivery ­vectors. Adv Exp Med Biol 465:57–63PubMedCrossRefGoogle Scholar
  4. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408–1416PubMedGoogle Scholar
  5. Chen G, Wei DP, Jia LJ et al (2009) Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity. Cancer Sci 100:2437–2443PubMedCrossRefGoogle Scholar
  6. Clairmont C, Lee KC, Pike J et al (2000) Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 181:1996–2002PubMedCrossRefGoogle Scholar
  7. Coley WB (1906) Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and Bacillus prodigiosus. Am J Med Sci 131:375–430Google Scholar
  8. Dang LH, Bettegowda C, Huso DL et al (2001) Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 98:15155–15160PubMedCrossRefGoogle Scholar
  9. Darji A, Guzmán CA, Gerstel B et al (1997) Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91:765–775PubMedCrossRefGoogle Scholar
  10. Forbes NS (2010) Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 10:785–794PubMedCrossRefGoogle Scholar
  11. Forbes NS, Munn LL, Fukumura D et al (2003) Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res 63:5188–5193PubMedGoogle Scholar
  12. Fox ME, Lemmon MJ, Mauchline ML et al (1996) Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered Clostridia. Gene Ther 3:173–178PubMedGoogle Scholar
  13. Fu W, Chu L, Han XW et al (2008) Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica serovar typhimurium in murine tumor models. J Gene Med 10:690–701PubMedCrossRefGoogle Scholar
  14. Gericke D, Engelbart K (1964) Oncolysis by Clostridia. II. Experiments on a tumor spectrum with a variety of clostridia in combination with heavy metal. Cancer Res 24:217–221PubMedGoogle Scholar
  15. Hayashi K, Zhao M, Yamauchi K et al (2009a) Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem 106:992–998PubMedCrossRefGoogle Scholar
  16. Hayashi K, Zhao M, Yamauchi K et al (2009b) Systemic targeting of primary bone tumor and lung metastasis of highgrade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle 8:870–875PubMedCrossRefGoogle Scholar
  17. Hoiseth SK, Stocker BA (1981) Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291:238–239PubMedCrossRefGoogle Scholar
  18. Jia LJ, Wei DP, Sun QM et al (2007) Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models. Cancer Sci 98:1107–1112PubMedCrossRefGoogle Scholar
  19. Kasinskas RW, Forbes NS (2006) Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng 94:710–721PubMedCrossRefGoogle Scholar
  20. Kasinskas RW, Forbes NS (2007) Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 67:3201–3209PubMedCrossRefGoogle Scholar
  21. Kimura NT, Taniguchi S, Aoki K et al (1980) Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 40:2061–2068PubMedGoogle Scholar
  22. Kimura H, Zhang L, Zhao M, et al (2010) Targeted therapy of spinal cord glioma with a ­genetically-modified Salmonella typhimurium. Cell Prolif 43:41–48Google Scholar
  23. Kohwi Y, Imai K, Tamura Z et al (1978) Antitumor effect of Bifidobacterium infantis in mice. Gann 69:613–618PubMedGoogle Scholar
  24. Lee CH, Wu CL, Shiau AL (2004) Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 6:1382–1393PubMedCrossRefGoogle Scholar
  25. Lemmon MJ, Van Zijl P, Fox ME et al (1997) Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 4:791–796PubMedCrossRefGoogle Scholar
  26. Leschner S, Westphal K, Dietrich N et al (2009) Tumor invasion of Salmonella enterica serovar typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One 4:e6692PubMedCrossRefGoogle Scholar
  27. Liu F, Zhang L, Hoffman RM et al (2010) Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity. Cell Cycle 9:4518–4524PubMedGoogle Scholar
  28. Low KB, Ittensohn M, Le T et al (1999) Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat Biotechnol 17:37–41PubMedGoogle Scholar
  29. Malmgren RA, Flanigan CC (1955) Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 15:473–478PubMedGoogle Scholar
  30. Mengesha A, Dubois L, Lambin P et al (2006) Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated Salmonella. Cancer Biol Ther 5:1120–1128PubMedCrossRefGoogle Scholar
  31. Moese JR, Moese G (1964) Oncolysis by Clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 24:212–216PubMedGoogle Scholar
  32. Nagakura C, Hayashi K, Zhao M et al (2009) Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res 29:1873–1878PubMedGoogle Scholar
  33. Nguyen VH, Kim HS, Ha JM et al (2010) Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res 70:18–23PubMedCrossRefGoogle Scholar
  34. Pawelek JM, Low KB, Bermudes D (1997) Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57:4537–4544PubMedGoogle Scholar
  35. Sznol M, Lin SL, Bermudes D et al (2000) Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest 105:1027–1030PubMedCrossRefGoogle Scholar
  36. Taniguchi S, Fujimori M, Sasaki T et al (2010) Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Sci 101(9):1925–1932PubMedCrossRefGoogle Scholar
  37. Thiele EH, Arison RN, Boxer GE (1964) Oncolysis by Clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res 24:222–233PubMedGoogle Scholar
  38. Toso JF, Gill VJ, Hwu P et al (2002) Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20:142–152PubMedCrossRefGoogle Scholar
  39. Weiss S, Chakraborty T (2001) Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers. Curr Opin Biotechnol 12:467–472PubMedCrossRefGoogle Scholar
  40. Westphal K, Leschner S, Jablonska J et al (2008) Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res 68:2952–2960PubMedCrossRefGoogle Scholar
  41. Yam C, Zhao M, Hayashi K et al (2010) Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 164:248–255PubMedCrossRefGoogle Scholar
  42. Yang N, Zhu X, Chen L et al (2008) Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic. Cancer Biol Ther 7:145–151PubMedCrossRefGoogle Scholar
  43. Yazawa K, Fujimori M, Amano J et al (2000) Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther 7:269–274PubMedCrossRefGoogle Scholar
  44. Yazawa K, Fujimori M, Nakamura T et al (2001) Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 66:165–170PubMedCrossRefGoogle Scholar
  45. Yu YA, Timiryasova T, Zhang Q et al (2003) Optical imaging: bacteria, viruses, and mammalian cells encoding light emitting proteins reveal the locations of primary tumors and metastases in animals. Anal Bioanal Chem 377:964–972PubMedCrossRefGoogle Scholar
  46. Yu YA, Shabahang S, Timiryasova TM et al (2004) Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 22:313–320PubMedCrossRefGoogle Scholar
  47. Zhang L, Gao L, Zhao L et al (2007) Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 67:5859–5864PubMedCrossRefGoogle Scholar
  48. Zhao M, Yang M, Li XM et al (2005) Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 102:755–760PubMedCrossRefGoogle Scholar
  49. Zhao M, Yang M, Ma H et al (2006) Targeted therapy with a Salmonella typhimurium leucine-­arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 66:7647–7652PubMedCrossRefGoogle Scholar
  50. Zhao M, Geller J, Ma H et al (2007) Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci USA 104:10170–10174PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.AntiCancer, Inc.San DiegoUSA
  2. 2.Department of SurgeryUniversity of California San DiegoSan DiegoUSA

Personalised recommendations